Long-Term Effects of Fenofibrate on Carotid Intima-Media Thickness and Augmentation Index in Subjects With Type 2 Diabetes Mellitus

Journal of the American College of Cardiology

Volumn 52, Issue 25, 2008, Pages 2190-2197

  Hiukka, Anne ^a   Westerbacka, Jukka ^a   Leinonen, Eeva S ^a   Watanabe, Hiroshi ^a   Wiklund, Olov ^b   Hulten, Lillemor Mattson ^b   Salonen, Jukka T ^c,d   Tuomainen, Tomi Pekka ^c   Yki Järvinen, Hannele ^a   Keech, Anthony C ^e   Taskinen, Marja Riitta ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

^c UNIVERSITY OF EASTERN FINLAND   (Finland)

^d Oy Jurilab Ltd   (Finland)

^e UNIVERSITY OF SYDNEY   (Australia)

Author keywords

augmentation index; fenofibrate; inflammation; intima media thickness; type 2 diabetes

Indexed keywords

C REACTIVE PROTEIN; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; FENOFIBRATE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; PLACEBO; SECRETORY PHOSPHOLIPASE A2; SERUM AMYLOID A; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; AGED; ARTERIAL STIFFNESS; ARTERIAL WALL THICKNESS; ARTICLE; ATHEROSCLEROSIS; AUGMENTATION INDEX; CELL ACTIVATION; CONTROLLED STUDY; DRUG EFFECT; ENDOTHELIUM; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; UNSPECIFIED SIDE EFFECT;

ACUTE-PHASE PROTEINS; AGED; ANTILIPEMIC AGENTS; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CAROTID ARTERIES; CAROTID ARTERY DISEASES; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; PROCETOFEN; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT FAILURE; TUNICA INTIMA; TUNICA MEDIA;

EID: 57449094179     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2008.09.049     Document Type: Article

References (38)

1. Haffner S.M., Lehto S., Ronnemaa T., Pyorala K., and Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339 (1998) 229-234
2. Juutilainen A., Lehto S., Ronnemaa T., Pyorala K., and Laakso M. Type 2 diabetes as a "coronary heart disease equivalent": an 18-year prospective population-based study in Finnish subjects. Diabetes Care 28 (2005) 2901-2907
3. Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 371 (2008) 117-125
4. Ceriello A., Taboga C., Tonutti L., et al. Evidence for an independent and cumulative effect of postprandial hypertriglyceridemia and hyperglycemia on endothelial dysfunction and oxidative stress generation: effects of short- and long-term simvastatin treatment. Circulation 106 (2002) 1211-1218
5. Tan K.C., Chow W.S., Tam S.C., Ai V.H., Lam C.H., and Lam K.S. Atorvastatin lowers C-reactive protein and improves endothelium-dependent vasodilation in type 2 diabetes mellitus. J Clin Endocrinol Metab 87 (2002) 563-568
6. Ceriello A., Assaloni R., Da Ros R., et al. Effect of atorvastatin and irbesartan, alone and in combination, on postprandial endothelial dysfunction, oxidative stress, and inflammation in type 2 diabetic patients. Circulation 111 (2005) 2518-2524
7. Muhlestein J.B., May H.T., Jensen J.R., et al. The reduction of inflammatory biomarkers by statin, fibrate, and combination therapy among diabetic patients with mixed dyslipidemia: the DIACOR (diabetes and combined lipid therapy regimen) study. J Am Coll Cardiol 48 (2006) 396-401
8. van de Ree M.A., Huisman M.V., Princen H.M., Meinders A.E., Kluft C., and DALI-Study Group. Strong decrease of high sensitivity C-reactive protein with high-dose atorvastatin in patients with type 2 diabetes mellitus. Atherosclerosis 166 (2003) 129-135
9. Takahashi T., Ishii N., Itai K., Goto R., Higashi K., and Kobori S. HMG-CoA reductase inhibitors suppress the development and progression of carotid artery intimal-medial thickening in hypercholesterolemic type 2 diabetic patients. J Atheroscler Thromb 12 (2005) 149-153
10. Shinohara K., Shoji T., Kimoto E., et al. Effect of atorvastatin on regional arterial stiffness in patients with type 2 diabetes mellitus. J Atheroscler Thromb 12 (2005) 205-210
11. Ichihara A., Hayashi M., Ryuzaki M., Handa M., Furukawa T., and Saruta T. Fluvastatin prevents development of arterial stiffness in haemodialysis patients with type 2 diabetes mellitus. Nephrol Dial Transplant 17 (2002) 1513-1517
12. Rubins H.B., Robins S.J., Collins D., et al. Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT). Arch Intern Med 162 (2002) 2597-2604
13. The BIP Investigators. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the bezafibrate infarction prevention (BIP) study. Circulation 102 (2000) 21-27
14. The DAIS Investigators. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the diabetes atherosclerosis intervention study, a randomised study. Lancet 357 (2001) 905-910
15. Zhu S., Su G., and Meng Q.H. Inhibitory effects of micronized fenofibrate on carotid atherosclerosis in patients with essential hypertension. Clin Chem 52 (2006) 2036-2042
16. Elkeles R.S., Diamond J.R., Poulter C., et al. Cardiovascular outcomes in type 2 diabetes. A double-blind placebo-controlled study of bezafibrate: the St. Mary's, Ealing, Northwick Park diabetes cardiovascular disease prevention (SENDCAP) study. Diabetes Care 21 (1998) 641-648
17. Chironi G., Simon A., Gariepy J., Balice M., Del-Pino M., and Levenson J. Differential associations of statin and fibrate treatment with carotid arterial remodeling. Am J Hypertens 18 (2005) 1476-1481
18. Blacher J., Guerin A.P., Pannier B., Marchais S.J., Safar M.E., and London G.M. Impact of aortic stiffness on survival in end-stage renal disease. Circulation 99 (1999) 2434-2439
19. Ryan K.E., McCance D.R., Powell L., McMahon R., and Trimble E.R. Fenofibrate and pioglitazone improve endothelial function and reduce arterial stiffness in obese glucose tolerant men. Atherosclerosis 194 (2007) e123-e130
20. Dogra G., Irish A., Chan D., and Watts G. A randomized trial of the effect of statin and fibrate therapy on arterial function in CKD. Am J Kidney Dis 49 (2007) 776-785
21. McKenney J.M., Farnier M., Lo K.W., et al. Safety and efficacy of long-term co-administration of fenofibrate and ezetimibe in patients with mixed hyperlipidemia. J Am Coll Cardiol 47 (2006) 1584-1587
22. Tanne D., Benderly M., Goldbourt U., et al. C-reactive protein as a predictor of incident ischemic stroke among patients with preexisting cardiovascular disease. Stroke 37 (2006) 1720-1724
23. Marchesi S., Lupattelli G., Lombardini R., et al. Effects of fenofibrate on endothelial function and cell adhesion molecules during post-prandial lipemia in hypertriglyceridemia. J Clin Pharm Ther 28 (2003) 419-424
24. Wang T.D., Chen W.J., Lin J.W., Cheng C.C., Chen M.F., and Lee Y.T. Efficacy of fenofibrate and simvastatin on endothelial function and inflammatory markers in patients with combined hyperlipidemia: relations with baseline lipid profiles. Atherosclerosis 170 (2003) 315-323
25. Koh K.K., Han S.H., Quon M.J., Yeal Ahn J., and Shin E.K. Beneficial effects of fenofibrate to improve endothelial dysfunction and raise adiponectin levels in patients with primary hypertriglyceridemia. Diabetes Care 28 (2005) 1419-1424
26. Field Study Investigators. The need for a large-scale trial of fibrate therapy in diabetes: the rationale and design of the fenofibrate intervention and event lowering in diabetes (FIELD) study. Cardiovasc Diabetol 3 (2004) 9-19
27. Hiukka A., Leinonen E., Jauhiainen M., et al. Long-term effects of fenofibrate on VLDL and HDL subspecies in participants with type 2 diabetes mellitus. Diabetologia 50 (2007) 2067-2075
28. Leinonen E.S., Salonen J.T., Salonen R.M., et al. Reduced IGFBP-1 is associated with thickening of the carotid wall in type 2 diabetes. Diabetes Care 25 (2002) 1807-1812
29. Westerbacka J., Wilkinson I., Cockcroft J., Utriainen T., Vehkavaara S., and Yki-Jarvinen H. Diminished wave reflection in the aorta. A novel physiological action of insulin on large blood vessels. Hypertension 33 (1999) 1118-1122
30. University of Southampton School of Medicine. Confidence Interval Analysis (CIA). http://www.som.soton.ac.uk/cia/ Accessed November 7, 2008
31. University of Helsinki Faculty of Medicine Department of Public Health. LR Test 2 × 2. http://www.kttl.helsinki.fi/sarna/Stats/LRtest2x2.xls Accessed November 7, 2008
32. Howard B.V., Roman M.J., Devereux R.B., et al. Effect of lower targets for blood pressure and LDL cholesterol on atherosclerosis in diabetes: the SANDS randomized trial. JAMA 299 (2008) 1678-1689
33. Graner M., James R.W., Kahri J., Nieminen M.S., Syvanne M., and Taskinen M.R. Association of paraoxonase-1 activity and concentration with angiographic severity and extent of coronary artery disease. J Am Coll Cardiol 47 (2006) 2429-2435
34. Stehouwer C.D., Henry R.M., and Ferreira I. Arterial stiffness in diabetes and the metabolic syndrome: a pathway to cardiovascular disease. Diabetologia 51 (2008) 527-539
35. Calabresi L., Gomaraschi M., Villa B., Omoboni L., Dmitrieff C., and Franceschini G. Elevated soluble cellular adhesion molecules in subjects with low HDL-cholesterol. Arterioscler Thromb Vasc Biol 22 (2002) 656-661
36. Hogue J.C., Lamarche B., Tremblay A.J., Bergeron J., Gagne C., and Couture P. Differential effect of atorvastatin and fenofibrate on plasma oxidized low-density lipoprotein, inflammation markers, and cell adhesion molecules in patients with type 2 diabetes mellitus. Metabolism 57 (2008) 380-386
37. Baldassarre D., De Jong A., Amato M., et al. Carotid intima-media thickness and markers of inflammation, endothelial damage and hemostasis. Ann Med 40 (2008) 21-44
38. Keech A., Simes R.J., Barter P., et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366 (2005) 1849-1861